News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VetDC Files Final TANOVEA FDA Submission For Use In Canine Lymphoma



11/17/2016 10:45:20 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

FORT COLLINS, Colo.--(BUSINESS WIRE)--VetDC, Inc., a veterinary cancer therapeutics company, today announced that the Company has completed all required major and minor technical sections for Tanovea™ (rabacfosadine for injection) and filed its administrative New Animal Drug Application (NADA) for conditional approval with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM).

“This is an incredibly exciting time for VetDC, as we are now in the home stretch toward introducing the first FDA-approved drug for use in dogs with lymphoma, one of the most common cancers affecting pets today”

The administrative NADA submission is the final step required for FDA conditional approval of Tanovea, and an approval decision is anticipated within 60 days. Upon FDA approval, VetDC intends to commence commercialization in early 2017.

“This is an incredibly exciting time for VetDC, as we are now in the home stretch toward introducing the first FDA-approved drug for use in dogs with lymphoma, one of the most common cancers affecting pets today,” stated Steven Roy, VetDC’s President and CEO.

About Tanovea

Tanovea™ (rabacfosadine for injection) is a novel small molecule drug designed to preferentially target and attack cancer cells implicated in lymphoma, one of the most common cancers seen in companion animals. In multiple clinical studies in over 300 client-owned dogs with naturally occurring lymphoma, Tanovea has consistently demonstrated robust anti-tumor activity in both naïve and relapsed cases, with a generally well-tolerated safety profile. Tanovea has a rapid onset of action and is being investigated as a convenient, every-three-week treatment for up to five doses, representing a substantial reduction in client visits relative to non-approved, ‘human’ generic multi-agent chemotherapy regimens commonly utilized in dogs with lymphoma.

VetDC has an exclusive North American license from Gilead Sciences to develop and commercialize Tanovea for companion animal cancer.

About VetDC, Inc.

VetDC (www.vetdc.com) is changing the way new cancer medicines are developed for companion animals, leveraging novel advancements from human biotechnology that have demonstrated success in animal studies. VetDC currently has two cancer programs in development, Tanovea for lymphoma and VDC-597 for multiple cancers.

Contacts

VetDC, Inc.
Steven Roy, 303-859-2072


Read at BioSpace.com


comments powered by Disqus
   
Lymphoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES